Antibiotic Treatment foLlowing Surgical drAinage of Perianal abScess; the ATLAS Trial (ATLAS)

Antibiotic Treatment foLlowing Surgical drAinage of Perianal abScess; the ATLAS Trial, a Double-blind, Placebo-controlled, Randomized Trial

Rationale:

Perianal fistula is a burdening disease with an annual prevalence of 2/100.000 in the Dutch population. More than 90% of crypto-glandular fistulas originate from anorectal abscess. Despite adequate drainage of anorectal abscess up to 83% recurs or results in an anal fistula, the majority developing within 12 months. Up till now it is not common practice to routinely administer prophylactic antibiotics to prevent anal fistula development.\

Objective:

The objective of this trial is to establish if adding antibiotic treatment to surgical drainage of perianal abscess results in less perianal fistulas.

Study design:

The study concerns a double-blind, placebo-controlled, randomized, multicenter trial with treatment of perianal abscess by surgical drainage alone or combined with antibiotic treatment. Patients will be accrued by all participating clinics. The design involves allocation of all appropriate consecutive patients with a primary occurrence of perianal abscess to surgical drainage followed by either antibiotics or placebo. Data will be analyzed on 'intention to treat' basis in case patients are not subjected to the randomized treatment modality.

Study population:

Men and women of 18 years and older who present for the first time with a perianal abscess.

Intervention (if applicable): The antibiotic group receives 7 days of oral metronidazole (500 mg every eight hours) and ciprofloxacin (500 mg every twelve hours) in addition to surgical drainage. The other group receives surgical drainage and postoperatively identical placebo tablets.

Main study parameters/endpoints:

Primary outcome measure is development of a perianal fistula. Secondary outcome measures are quality of life at 12 months measured with the EQ-5D-5L with Dutch rating. Further: in-hospital direct and indirect costs and out-of hospital postoperative costs, need of repeated drainage, patient related outcome (PRO) and clinical outcome measures.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

For this study, patients are asked to take part in a study comparing the addition of antibiotic treatment to surgical drainage of perianal abscess. Patients will not be burdened by extra hospital visits. At baseline participants will complete PRO questionnaires. Also at 1 week and 3, 6 and 12 months participants will fulfill the PRO questionnaires. These will be send to them by email and will take approximately 10 minutes each time.

Study Overview

• Status: Recruiting
• Conditions: Drain Abscess; Perianal Abscess; Perianal Fistula
• Intervention / Treatment: Drug: Placebo; Drug: Ciprofloxacin 500 mg; Drug: Metronidazole 500 mg

• Study Type: Interventional
• Enrollment (Estimated): 298
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Ingrid M Han-Geurts, Dr.; Phone Number: 030 225 0260; Email: i.han@proctoskliniek.nl
• Study Contact Backup: Name: Justin Y van Oostendorp, Drs.; Phone Number: 030 225 0260; Email: j.vanoostendorp@proctoskliniek.nl

Study Locations

• Netherlands
  • Almere, Netherlands
    • Recruiting
    • Flevoziekenhuis
    • Contact: Ruben Schouten, dr.; Email: ruschouten@flevoziekenhuis.nl
  • Amsterdam, Netherlands
    • Recruiting
    • University Medical Center location AMC
    • Contact: Willem M Bemelman, prof. dr.
  • Capelle Aan Den IJssel, Netherlands
    • Recruiting
    • IJsselland Ziekenhuis
    • Contact: Oddeke van Ruler, dr.; Email: ovruler@ysl.nl
  • Utrecht, Netherlands
    • Recruiting
    • Diakonessenhuis
    • Contact: Anandi Schiphorst, dr.; Email: aschiphorst@diakhuis.nl
  • Noord-Brabant
    • Tilburg, Noord-Brabant, Netherlands, 5022 GC
      • Recruiting
      • Elisabeth-TweeSteden Ziekenhuis
      • Contact: David Zimmerman, Dr.; Email: d.zimmerman@etz.nl
  • Noord-Holland
    • Beverwijk, Noord-Holland, Netherlands, 1942 LE
      • Recruiting
      • Rode Kruis Ziekenhuis
      • Contact: Frederik Jonker, Dr.; Email: fjonker@rkz.nl
  • North-Brabant
    • Breda, North-Brabant, Netherlands, 4818 CK
      • Recruiting
      • Amphia Hospital
      • Contact: Ninos Ayez, Dr.; Email: nayez@amphia.nl
  • North-Holland
    • Amsterdam, North-Holland, Netherlands, 1091 AC
      • Recruiting
      • OLVG
      • Contact: Steve de Castro, Dr.; Email: S.M.M.deCastro@olvg.nl
    • Hoorn, North-Holland, Netherlands, 1624 NP
      • Recruiting
      • Dijklander Hospital
      • Contact: Marc Govaert, Dr.; Email: m.j.p.m.govaert@dijklander.nl
  • Utrecht
    • Bilthoven, Utrecht, Netherlands, 3723 MB
      • Recruiting
      • Proctos Kliniek
      • Contact: Ingrid M Han-Geurts, Dr; Email: i.han@proctoskliniek.nl
  • Zuid-Holland
    • Dordrecht, Zuid-Holland, Netherlands, 3318 AT
      • Recruiting
      • Albert Schweitzer Ziekenhuis
      • Contact: Robert Smeenk, Dr.; Email: r.m.smeenk@asz.nl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Men and women aged 18 years or older
• Eligible for e-mail questionnaires
• Sufficient understanding of the Dutch written language (reading and writing)
• Obtained written informed consent

Exclusion Criteria:

• A coexistent anorectal fistula
• Secondary or recurrent anorectal abscess
• Presence of an internal fistula opening
• Any additional surgical procedure performed during the same session
• Previous (peri)anal surgery
• Inflammatory bowel disease
• History of radiation of the pelvic area
• Anorectal malignancy
• Immunodeficiency
• Kidney failure (eGFR <30ml/min)
• Valvular heart disease
• Pregnancy or lactation
• Postoperative antibiotic prophylaxis indicated for another reason
• Immunosuppressive medication at the time of surgery
• Allergy to metronidazole or ciprofloxacin
• Not able or trouble with swallowing pills

• Concomitant use of:

  • Tizanidine, theophylline, clozapine, olanzapine, pirfenidone, carbamazepine, agomelatine (these are all CYP1A2 substrates, ciprofloxacin is an inhibitor)
  • Amiodarone, erythromycin, sotalol, azithromycin, citalopram, escitalopram, flecainide, fluconazole, haloperidol >5mg/day, methadone, ondansetron (concerning prolonged QT interval in combination with ciprofloxacin)
  • Lithium (can cause toxic levels with metronidazole)
  • Lopinavir/ritonavir, ritonavir capsules, temsirolimus, disulfiram (antabuse), mebendazole (can cause serious side effects, confusion and psychosis in combination with metronidazole)
  • Corticosteroids (in combination with ciprofloxacin higher risk of tendinitis and tendon rupture).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Antibiotic treatment; Two kinds of antibiotics: Ciprofloxacine 500mg 2dd & Metronidazole 500mg 3dd	Drug: Ciprofloxacin 500 mg; One tablet of 500mg Ciprifloxacine, twice a day; Drug: Metronidazole 500 mg; One tablet of 500mg Metronidazole, three times a day
Placebo Comparator: Placebo; Placebo tabletes	Drug: Placebo; Placebo tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Perianal fistula at 1 year follow up	A perianal fistula is diagnosed based on findings from physical examination or by a telephone call after 12 months were the doctor asks for symptoms as serosanguinous discharge and pain. An external opening with or without serosanguilent discharge is considered a fistula. In case of doubt an endoanal ultrasonography or MRI is performed. So: yes/no fistula (dichotomous parameter)	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of life at 12 months measured with the EQ-5D-5L with Dutch rating.	The EQ-5D-5L is a generic Health Related Quality of Life (HRQoL) measure, which is broadly used in economic evaluation. The instrument examines a patient's HRQoL on the day of the interview. It consists of the EQ-5D-5L descriptive system and the EQ-Visual Analogue Scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has five levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses to the 5 items result in a patient's health state that can be transformed into an index score representing health-related quality of life, ranging between 0 (death) and 1 (full health). These index scores are combined with length of life to calculate the QALY. The EQ-VAS records the patient's self-rated health with endpoints labelled 'the best health you can imagine' at the top and 'the worst health you can imagine' at the bottom.	1 year
In-hospital direct and indirect costs and out-of hospital posteroperative costs	In-hospital direct and indirect costs (measured with iPCQ and iMCQ) and out-of hospital postoperative costs.	1 year
Need of repeated drainage		1 year
PROMs	Patient related outcome (PRO) are complaint reduction assessed by a proctology specific validated patient-related outcome measure, the proctoPROM(14). This was recently developed and validated at Proctos Clinic. At baseline participants will complete PRO questionnaires. Also at 1 week and 3, 6 and 12 months participants will fulfill the PRO questionnaires. These will be send to them by email with access to a web tool (Castor). If the patient does not have an email account, the questionnaires will be send the patients' home address, accompanied by a return envelope provided with postage stamps and the address of the hospital.	1 year
Day of discharge from hospital	Day of discharge from hospital;	1 year
Postoperative complications	Complications (postoperative bleeding, urinary retention requiring catheterisation, emergency reoperation, anal stenosis and fecal incontinence) including death and cause of death within 30 days will be reported using the Clavien-Dindo classification of surgical complications(15).	1 year
Recurrent abscess	(Recurrent) abscess within one year. Yes/no (dichotomous)	1 year
Duration of absence from work	Duration of absence from work. Amound of days is recorded (continuous scale)	1 year

Collaborators and Investigators

• Sponsor: dr. IJM Han-Geurts
• Collaborators: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Publications and helpful links

General Publications

• van Oostendorp JY, Dekker L, van Dieren S, Bemelman WA, Han-Geurts IJM. Antibiotic Treatment foLlowing surgical drAinage of perianal abScess (ATLAS): protocol for a multicentre, double-blind, placebo-controlled, randomised trial. BMJ Open. 2022 Nov 8;12(11):e067970. doi: 10.1136/bmjopen-2022-067970.

Study record dates

Study Major Dates

• Study Start (Actual): December 23, 2021
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): August 1, 2025

Study Registration Dates

• First Submitted: May 12, 2022
• First Submitted That Met QC Criteria: May 17, 2022
• First Posted (Actual): May 23, 2022

Study Record Updates

• Last Update Posted (Estimated): November 13, 2023
• Last Update Submitted That Met QC Criteria: November 10, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: perianal fistula; antibiotics; antibiotic treatment; perianal abscess; drainage of abscess
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Inflammation; Pathological Conditions, Anatomical; Suppuration; Fistula; Abscess; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Anti-Bacterial Agents; Cytochrome P-450 Enzyme Inhibitors; Antiprotozoal Agents; Antiparasitic Agents; Cytochrome P-450 CYP1A2 Inhibitors; Metronidazole; Ciprofloxacin
• Other Study ID Numbers: NL75540.018.20; 2020-004449-35 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: A data management plan (DMP) will be composed containing the FAIR principles. Existing data will be used, and new data will be generated. Data are registered in an archive or repository and open access will be enabled. Results will be disclosed in a peer review medical journal to guarantee transparency. The study protocol was registered in an open access public trial registry before recruitment started.
• IPD Sharing Time Frame: Within one year after the last study visit of the last patient. Data will be availabe for 15 years.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No